linjc16/ctgov huggingface dataset:
Optimized Camera-based Patient Positioning in CT

Study Overview
=================
Brief Summary
-----------------
To evaluate the effect on radiation dose using intelligent camera positioning in comparison to manual positioning by the radiology assistant.

Detailed Description
-----------------
The positioning of the patient at the beginning of every CT examination has an major influence on the image quality and especially on the respective effective patient dose in the CT scan. If the patient position is closer to the X-ray tube, the patient dose increases significantly and if the vertical patient position is chosen too far away from the X-ray tube, the applied dose decreases, but also the image quality. In a retrospective observational study, patients were examined on the CT scanner Somatom X.Cite and divided into two groups, one group was with intelligent camera positioning and the other with manual positioning. The patients received their CT scan at the Institute Radiology and Nuclear Medicine at the Nuremberg North Hospital strictly according to the clinical indication and without influence of the study.

Official Title
-----------------
Optimized Camera-based Patient Positioning in CT: Impact on Radiation Exposure.

Conditions
-----------------
Radiation Dosage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Only patients with a clinical indication for a CT Scan Exclusion Criteria: renal insufficiency, manifest hyperthyroidism and pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experimental group<br>patients positioned with 3D camera | |
| control group<br>patients positioned by experienced radiology assistants | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effective dose | the absorbed dose to different organs of the body | 10 months |
Maximal Inspiratory Pressure at Extubation: Relationship With Mortality

Study Overview
=================
Brief Summary
-----------------
The process of weaning from mechanical ventilation was decided after clinical judgment and weaning predictive index. Nevertheless, indexes predicting weaning outcome like Maximal Inspiratory Pressure (MIP) are frequently inaccurate. However the long-term involvement of respiratory muscles in critically ill patients has not been established. The objective of this study was to assess the relationship on MIP at extubation on one-year mortality in critically ill patients.

Conditions
-----------------
Mechanical Ventilation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mechanical ventilation at least at 24 hours Exclusion Criteria: Delirium Cognitive dysfunction refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients under mechanical ventilation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | One year after extubation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to mechanical ventilation weaning |  | During Intensive care unit hospitalization |
HPV Prevalence in Transpersons - a Prospective Study

Study Overview
=================
Brief Summary
-----------------
In this study, Human Papilloma Virus (HPV) prevalence will be determined once in the urine of 200 trans people. In addition, subjects will be asked to complete a questionnaire about their sexual orientation, which is adapted from the largest published study.

Detailed Description
-----------------
All transpeople who visit the outpatient clinic are asked to participate in the study. After being informed and signing the Informed Consent Form, the subjects are asked to give first-void urine and fill out the survey. The urine samples are sent pseudonymously to the University of Ljubljana for analysis. The subjects will be informed about their results within 3 weeks.If the result is positive, the subjects will be offered voluntary further care in our HPV outpatient clinic. However, this will take place outside the study. The data collected there can be used for further analyses.

Official Title
-----------------
HPV Prevalence in Transpersons - a Prospective Study

Conditions
-----------------
Papillomavirus Infection, Transsexualism

Intervention / Treatment
-----------------
* Diagnostic Test: Colli-Pee urine collection device
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Transpeople Age over 18 years Sufficient knowledge of German Exclusion Criteria: Age under 18 years Insufficient knowledge of German

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Transpeople<br>1x urine sampling for HPV analysis 1x survey | Diagnostic Test: Colli-Pee urine collection device<br>* first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.<br>Other: Survey<br>* Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HPV prevalence in transpeople | HPV prevalence in transpeople | one year |
Preoperative Magnetic Resonance Imaging Abnormalities Predictive of Lumbar Herniation Recurrence

Study Overview
=================
Brief Summary
-----------------
There are currently no standard criteria for evaluating the risk of recurrent disk herniation following surgical repair. This study investigated the predictive values of five presurgical imaging parameters, paraspinal muscle quality, annular tear size, Modic changes, modified Pfirrmann's disc degeneration grade, and presence of sacralization or fusion. Clinical status and MRI findings were evaluated before surgery and 4, 12, and 24 months post-surgery using a Visual Analog Scale (VAS), Oswestry Disability Index (ODI), and Short Form 36 (SF36).

Official Title
-----------------
Preoperative Magnetic Resonance Imaging Abnormalities Predictive of Lumbar Herniation Recurrence Following Surgical Repair

Conditions
-----------------
Lumbar Disc Herniation

Intervention / Treatment
-----------------
* Device: magnetic resonance imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first operation for a single-level lumbar disk herniation no concurrent spinal pathology such as stenosis, spondylolisthesis, or deformity complete data on clinical and radiological parameters Exclusion Criteria: the operation was for multi-level pathologies recurrent surgery exhibited concurrent spinal pathology was missing or incomplete clinical and radiological data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: magnetic resonance imaging|Preoperative magnetic resonance imaging|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Paraspinal muscle quality | Simplified 3-tier classification | Preoperative 1 month | 
| Annular tear size | With computer as millimeter | Preoperative 1 month | 
| Modic changes | Modic classification | Preoperative 1 month | 
| Disc degeneration grade | modified Pfirrmann's classification | Preoperative 1 month | 
| sacralization or fusion | MRI findings | Preoperative 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analog Scale | 0-10 numerical scale (0=no pain, 10 =the worst pain) | 4, 12, and 24 months after surgery | 
| Oswestry Disability Index (ODI) | Oswestry Low Back Pain Disability Questionnaire | 4, 12, and 24 months after surgery | 
| Short Form 36 (SF36) | SF-36 Questionnaire | 4, 12, and 24 months after surgery |
An Oral Nutritional Supplement Study in Older Malnourished Spanish Population

Study Overview
=================
Brief Summary
-----------------
Post-marketing observational study of a nutritional care plan, including a higher calorie, higher protein oral nutritional supplement (ONS), prescribed to Spanish patients, both free living and residing and nursing homes, who have been identified as malnourished. The objective is to assess the impact of the ONS on body weight, activities of daily living and quality of life.

Official Title
-----------------
A Prospective, Observational Study, of a High Calorie and Protein Oral Nutritional Supplement, in an Older Malnourished Spanish Population

Conditions
-----------------
Malnutrition

Intervention / Treatment
-----------------
* Other: Nutritional Supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to any participation in the study. Considered malnourished, or is at risk for malnutrition based on NRS 2002 score ≥3. ≥65 years of age. Conforms to the requirements set forth on the study product label. Under the care of a health care professional for malnutrition and has recently (within the last 7 days prior to participating in this study) been prescribed 2 servings/d of the study ONS, orally, by their health care professional. Free living or residing in a nursing home. Estimated, or measured, glomerular filtration rate >60ml/min/1.73m2 (Modification of Diet in Renal Disease (MDRD) Study equation) within 60 days of beginning their nutritional care plan. Body mass index (BMI) is <30 kg/m2. Study physician determines the subject is fit to participate.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nutritional Supplement<br>Free living and residing and nursing home malnourished patients | Other: Nutritional Supplement<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Weight |  | Change from baseline to 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Mass Index (BMI) | BMI will be calculated: weight (kg)/ height (cm)^2 | Change from baseline to 12 weeks | 
| Katz Activities of Daily Living | A standardized, validated tool that asks about independence in bathing, dressing, toileting, transferring, continence and feeding. | Change from baseline to 12 weeks | 
| Quality of Life | EQ5D, self-reported quality of life tool | Change from baseline to 12 weeks |
Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus

Study Overview
=================
Brief Summary
-----------------
The objective of this prospective randomized and double blind controlled study is to evaluate the efficacy and safety of Sulodexide (25 mg) in the treatment of chronic idiopathic subjective tinnitus.

Detailed Description
-----------------
Patients with chronic idiopathic subjective tinnitus, since at least 1 year, re recruited from our Ear, Nose and Throat (ENT) clinic. After verification of inclusion and exclusion criteria, patients consenting to enter the study are assigned randomly to one of the following groups: 1- Sulodexide 25 mg for 40 days 2- Placebo for 40 days. Clinical evaluation of the patient is performed; tinnitus is assessed according to Tinnitus Handicap Inventory score, Mini Tinnitus Questionnaire score. Adverse effects are also noted. Patients are followed at 40 days post-treatment and outcome measures are assessed.

Official Title
-----------------
Randomized Double Blind Controlled Trial on Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus

Conditions
-----------------
Tinnitus, Subjective

Intervention / Treatment
-----------------
* Drug: Sulodexide
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tinnitus for minimum of 1 year Absence of psychiatric or neurological diseases Absence of any disease that explains tinnitus Noise-induced hearing loss Cochlear and retro-cochlear damage Exclusion Criteria: Conductive hearing loss Mixed hearing loss Meniere's disease Systemic vascular disease Diabetic disease Vestibular schwannoma Cerebello-pontine angle tumors Pulsatile tinnitus Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Sulodexide<br>Sulodexide 25 mg twice per day for 40 days | Drug: Sulodexide<br>* 25 mg morning and evening for 40 days<br>|
| Placebo Comparator: Placebo<br>1 tablet twice per day for 40 days | Drug: Placebo<br>* 1 tablet morning and evening for 40 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tinnitus Handicap Inventory (THI) | Assessment of changes in THI questionnaire score between Day 40 and 0 | At day 0 and at 40 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mini Tinnitus Questionnaire (Mini-TQ) | Assessment of changes in Mini-TQ questionnaire score between Day 40 and 0 | At day 0 and at 40 days | 
| Adverse effects | reporting adverse effects by the patient | Up to 40 days |
Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia

Study Overview
=================
Brief Summary
-----------------
Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.

Official Title
-----------------
Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia

Conditions
-----------------
Bone Fibrous Dysplasia

Intervention / Treatment
-----------------
* Biological: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with fibrous dysplasia of the bone access to social security informed consent Exclusion Criteria: no informed consent pregnancy patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis…)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with bone fibrous dysplasia<br>Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum | Biological: Blood sampling<br>* Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum<br>|
| No Intervention: Control subjects<br>Control subjects will have no intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Periostin rate in serum |  | At inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Periostin rate in serum according to the number of fibrotic bones |  | At inclusion | 
| Periostin rate in serum in patients with severe phenotype of the disease |  | At inclusion | 
| Periostin rate in serum in patients with Mac Cune Albright syndrome |  | At inclusion |
Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function

Study Overview
=================
Brief Summary
-----------------
To validate a new methodology, named Retinal Leakage Analysis (RLA), for mapping the human Blood-Retinal Barrier (BRB) function, in the clinical practice.

Official Title
-----------------
Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function

Conditions
-----------------
Age-Related Maculopathy, Diabetic Macular Edema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with AMD, or Patients diagnosed with DME Age over 18 years Inform consent Exclusion Criteria: Cataract or other eye disease that may interfere with fundus examinations Glaucoma Dilatation of the pupil < 5 mm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AMD<br>Patients diagnosed with AMD | |
| DME<br>Patients diagnosed with DME | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood-Retinal Barrier (BRB) function measured by Retinal Leakage Analysis (RLA). |  |  |
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease. Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.

Official Title
-----------------
A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period

Conditions
-----------------
Alzheimer's Disease, Dementia

Intervention / Treatment
-----------------
* Drug: Donepezil hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically diagnosed Alzheimer's Disease with MMSE score 1 12 Have not been treated by any medication for Alzheimer's Disease in past 3 months Live in community or Assisted Living Facility Healthy or with chronic diseases that are medically controlled or stabilized Able to swallow tablets Exclusion Criteria: Any primary neurological or psychiatric diagnosis (including depressive disorder) other than Alzheimer's Disease Dementia caused by organic diseases other than Alzheimer's Disease

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Donepezil hydrochloride|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessments of global and cognitive function of Severe AD patients |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of behavior and performance on Activity of Daily Living in severe AD patients |  |  | 
| Assessment of caregiver burden |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer's Disease, dementia, acetylcholinesterase, donepezil, Aricept, memory loss, Severe dementia of the Alzheimer's type